Nimbus Therapeutics Regains Worldwide Rights to HPK1 Inhibitor Program from Bristol Myers Squibb

– Supported by positive preclinical data, Nimbus will pursue IND submission for HPK1 inhibitor candidate in 2021 –

CAMBRIDGE, Mass. – Dec. 30, 2020 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced that it has regained the worldwide rights to its HPK1 inhibitor program from Bristol Myers Squibb. Under Nimbus’ agreement with Celgene, now a Bristol Myers Squibb company, Celgene held an option to acquire the HPK1 inhibitor program. As part of its Celgene integration process, Bristol Myers Squibb is streamlining and prioritizing its portfolio and as a result, made the decision to decline this option.

“We’re excited to continue progressing our small molecule HPK1 inhibitors within Nimbus’ wholly owned pipeline. Preclinical data we presented this year at prominent oncology conferences show that our potent HPK1 inhibitor has a high degree of selectivity, demonstrates in vitro effects on T cells, B cells and dendritic cells, and shows significant in vivo tumor growth inhibition across multiple animal models,” said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. “We look forward to progressing this promising immuno-oncology program into a first-in-human clinical study in 2021.”

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass.

Media Contact

Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications